| Predicate |
Object |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6911
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6929 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-706 |
| filingDate |
2015-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017538783-A |
| titleOfInvention |
Pharmaceutical composition, its preparation and use |
| abstract |
The invention is administered to a subject in need of such a pharmaceutical compound comprising a combination of (i) at least one biocompatible nanoparticle and (ii) at least one carrier comprising at least one pharmaceutical compound. A pharmaceutical composition for use in which a combination of the at least one biocompatible nanoparticle and the at least one carrier comprising the pharmaceutical compound increases the efficiency of the compound of interest. The longest dimension of the biocompatible nanoparticle is typically between about 4 nm and about 500 nm, and the absolute value of its surface charge is at least 10 mV (| 10 mV |). Furthermore, the carrier is free of any surface steric stabilizer. The invention also provides such a composition for use in administering the pharmaceutical compound to a subject in need thereof, comprising the at least one nanoparticle and the at least one pharmaceutical compound. The composition wherein the at least one carrier is to be administered separately in a subject in need of the pharmaceutical compound, typically between more than 5 minutes and about 72 hours from each other . |
| priorityDate |
2014-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |